68 Ga-DOTATATE PET/CT for Neuroblastoma Staging: Utility for Clinical Use.

Metaiodobenzylguanidine (MIBG) imaging has been the standard for neuroblastoma staging for many decades. Novel agents such as ¹⁸ F-DOPA and ⁶⁸ Ga-DOTATATE are being used nowadays in academic centers. During the coronavirus disease 2019 (COVID-19) pandemic, procurement of ¹²³ I-MIBG has proved particularly challenging, necessitating the use of ⁶⁸ Ga-DOTATATE PET. ⁶⁸ Ga-DOTATATE is Food and Drug Administration-approved for imaging of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Methods: ⁶⁸ Ga-DOTATATE PET/CT imaging was performed for staging of 3 pediatric patients with neuroblastoma at our institution. A review of the literature was also completed. Results: ⁶⁸ Ga-DOTATATE PET/CT scans were successfully performed on all patients. All patients showed ⁶⁸ Ga-DOTATATE-avid disease. PET scans showed an excellent spatial resolution and demonstrated high accuracy in concordance with current European Association of Nuclear Medicine guidelines. Conclusion: We have presented ⁶⁸ Ga-DOTATATE PET/CT imaging for staging of neuroblastoma and believe it can reliably be used as an alternative to ¹²³ I-MIBG. It has technical, clinical, and practical advantages making it an attractive option. Further multicenter studies are required before it can be recommended for standard clinical use.
(© 2021 by the Society of Nuclear Medicine and Molecular Imaging.)